Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering
Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering
On Friday, Alumis Inc (NASDAQ:ALMS) priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering.
上周五，Alumis Inc（纳斯达克：ALMS）将其首次公开发行定价为16美元/股，低于区间的16-18美元，通过发行1313万股筹集了2.1亿美元。
Earlier, the company anticipated offering 17.65 million, raising $274 million and $315 million if the underwriters' over-allotment option is fully exercised.
此前，该公司预计发行募资额为2.74亿美元、3.15亿美元（如承销商超额配股选项被充分行使）。
In addition, Alumis has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,968,750 shares.
此外，Alumis授予承销商30天超额配股权，可以购买多达1,968,750股。
In addition to the shares being sold in the initial public offering, Alumis also announced that it has agreed to sell an additional 2.5 million shares in a concurrent private placement at $16.00 per share to AyurMaya Capital Management Fund, LP, its existing shareholder.
除了首次公开发行中出售的股份外，Alumis还宣布已同意以16.00美元/股的价格向其现有股东AyurMaya Capital Management Fund, LP定向增发2.5万股。
The shares are expected to begin trading on the Nasdaq on June 28, 2024, under the symbol "ALMS."
这些股票预计于2024年6月28日在纳斯达克上市，股票代码为“ALMS”。
Alumis is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
Alumis是一家处于临床阶段的生物制药公司，正在开发用于治疗免疫介导疾病的口服疗法。
Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies.
借助其专有的精确数据分析平台，Alumis正在建立一个潜在适用于单药治疗或联合治疗的分子流水线，以应对广泛范围的免疫介导疾病。
Alumis' most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of TYK2 that is currently being evaluated for moderate-to-severe plaque psoriasis and systemic lupus erythematosus.
Alumis的最先进的产品候选，ESK-001，是一种口服、高选择性、小分子、变构酶抑制剂，目前正在评估其对中度至重度鳞屑性银屑病和系统性红斑狼疮的疗效。
In March, the company presented clinical data from a Phase 2 clinical trial of ESK-001 in patients with moderate-to-severe plaque psoriasis.
今年3月，该公司发表了ESK-001在中度至重度鳞屑性银屑病患者中的2期临床试验数据。
Alumis plans to initiate Phase 3 trials of ESK-001 in moderate-to-severe plaque psoriasis in the second half of 2024.
Alumis计划在2024年下半年启动ESK-001对中度至重度鳞屑性银屑病的3期试验。
Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, with potential application in multiple sclerosis and Parkinson's.
Alumis还正在开发A-005，这是一种通过血脑屏障的变构酶抑制剂，可用于处理神经炎症和神经退行性疾病，可在多发性硬化和帕金森病等疾病中应用。
In April, the company initiated dosing in a Phase 1 trial of A-005 in healthy participants.
今年4月，该公司在健康志愿者中启动了A-005的1期试验。
Beyond TYK2, Alumis' proprietary precision data analytics platform and drug discovery expertise have identified additional preclinical programs.
除了TYK2外，Alumis的专有精确数据分析平台和药物发现专业技能还发现了其他潜在的临床前项目。
Price Action: ALMS shares were trading at $12.77 at the last check on Friday.
股价活动：上周五，ALMS股票价格为12.77美元。
Photo via Shutterstock
图片来自shutterstock。